SDGR - Schrodinger, Inc.
vs
Region: US
Website: schrodinger.com
Employees: 790
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The Software segment is focused on selling its software for drug discovery in the life sciences industry. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations.
Schrödinger Presents New Preclinical Data at AACR Annual Meeting
CHICAGO, April 28, 2025--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. The poster also described how the dosing schedule of SGR-3515 can be optimized to preserve efficacy and minimize target-related si
Read moreSchrödinger, Inc. (SDGR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential
We recently published a list of Bill Gates’ 10 Stock Positions with Huge Upside Potential. In this article, we are going to take a look at where Schrödinger, Inc. (NASDAQ:SDGR) stands against other top stocks in Bill Gates’ portfolio with huge upside potential. Bill Gates became the youngest billionaire back in 1987 when he took […]
Read moreSchrödinger to Announce First Quarter 2025 Financial Results on May 7
NEW YORK, April 23, 2025--Schrödinger will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close.
Read more